OncoNano Closes Additional $23.7 Million in Second Tranche of Series A Financing, Bringing Total Series A Raise to $35.4 Million

OncoNano公司A轮融资新增2370万美元,计划推动癌症成像临床试验

2019-07-11 13:00:00 BioSpace

本文共855个字,阅读需3分钟

Proceeds will be used to support new and ongoing cancer imaging clinical trials and to advance development of its pH-activated compound platform for cancer therapeutics and vaccines OncoNano Medicine, Inc. today announced the completion of $23.7 million in a second tranche of Series A financing, bringing the total Series A round to $35.4 million. The round was arranged by Salem Partners, who also participated as a principal investor. Proceeds of the financing will fuel OncoNano’s cancer imaging clinical trials and support the expansion of its technology into candidates for therapeutic applications. “Over the last year, OncoNano has made significant strides in the completion of a Phase 1 trial for our intraoperative cancer imaging agent, ONM-100, which saw a 100 percent imaging response in patients, as well as the expansion of the use of our pH sensitive micelle platform into exciting new areas such as therapeutics and cancer vaccines,” said Ravi Srinivasan, CEO of OncoNano Medicine. “The continued support of our distinguished investors and the addition of new investors into the OncoNano family will enable us to further our mission to change how cancer is detected and treated.” ONM-100 is the first product in a platform based upon the company’s library of unique micelles that are ultra-sensitive to changes in pH. The intravenously administered imaging agent, which detects tumors and metastatic lymph nodes, is entering a Phase 2 clinical trial. The company announced earlier this year that the U.S. Food and Drug Administration (FDA) accepted its Investigational New Drug (IND) application for ONM-100 and granted a Fast Track designation in response to a separate application. OncoNano’s micelle platform is also being used to develop therapeutics, including a T-cell activator that targets lymph nodes and dendritic cells to treat cancers. “The combination of OncoNano’s experienced executive and scientific team coupled with the progress the company is making in expanding the platform across multiple imaging and therapeutic applications underscores the tremendous interest in the company from both existing and new investors,” said John Dyett, Co-Founder and Managing Director at Salem Partners, who also serves on OncoNano’s Board of Directors. “We have full confidence in the company’s potential to make a significant impact in the future of cancer care.”
所得款项将用于支持新的和正在进行的癌症成像临床试验,并推动开发其用于癌症治疗和疫苗的 pH 激活化合物平台 OncoNano Medicine , Inc .今日宣布完成第二批 A 系列融资2370万美元,使 A 系列融资总额达到3540万美元。这轮融资由 Salem Partners 安排,后者也是一名主要投资者。融资所得将推动 OncoNano 的癌症成像临床试验,并支持将其技术扩展到治疗应用的候选领域。 “在过去的一年中, OncoNano 在完成我们的术中肿瘤成像剂 ONM-100的第1阶段试验方面取得了重大进展,在患者中看到了100%的成像反应,并将我们的 pH 敏感胶束平台的使用扩展到令人兴奋的新领域,如治疗学和癌症疫苗。OncoNano Medicine 首席执行官拉维•斯里尼瓦桑( Ravi Srinivasan )表示。“我们杰出投资者的持续支持,以及 OncoNano 家族新投资者的加入,将使我们能够进一步推进我们的使命,改变癌症检测和治疗的方式。” ONM-100是基于该公司独特胶束库的平台上的第一个产品,这些胶束对 pH 值的变化非常敏感。静脉注射成像剂,检测肿瘤和转移淋巴结,正在进入第二期临床试验。该公司今年早些时候宣布,美国食品药品监督管理局(Food and Drug Administration)( FDA )接受了其 ONM-100的调查新药( IND )申请,并根据一份单独的申请授予了快速通道标志。OncoNano 的胶束平台也被用于开发治疗药物,包括一种针对淋巴结和树突状细胞治疗癌症的 T 细胞激活剂。 “ OncoNano 经验丰富的高管和科学团队的结合,再加上该公司在跨多个成像和治疗应用领域扩展该平台方面取得的进展,突显出现有和新投资者对该公司的巨大兴趣,” John Dyett 说。同时担任 OncoNano 董事会成员的 Salem Partners 联合创始人兼董事总经理。“我们对该公司在未来癌症治疗领域产生重大影响的潜力充满信心。”

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文